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)e earliest clinical manifestation of SSc is usually Raynaud’s phenomenon, a small-arteries vasospasm driven by vascular tone
dysregulation andmicrocirculatory abnormalities, resulting in digital ulcers (DU) in up to 50% of patients. Many cytokines as well
as growth factors have been shown to play a role in promoting vascular smooth muscle cell proliferation and fibroblast activation,
leading to ischemic damage as well as skin fibrosis.We aim to investigate a possible difference in venous and arterial blood levels of
many cytokines ()1- and)17-related), GM-CSF, and endothelin-1 (ET1) in patients with and without DU. In the same patients,
the correlations between capillary damage, evaluated by nailfold videocapillaroscopy (NVC), extension of skin fibrosis, calculated
by modified Rodnan skin score (mRSS), and cytokines, ET-1, and GM-CSF levels were also measured. Patients with DU showed
venous levels of IL-1β (p � 0.024), IL-6 (p � 0.012), IL-22(p � 0.006), and TGF-β (p � 0.046) significantly higher compared to
arterial levels and arterial levels of GM-CSF and TNF-alpha significantly higher compared to venous levels (p< 0.001). NVC
abnormalities were correlated with arterial TNFa and venous IL22, IL23, and IL17 levels and negatively correlated with venous
ET-1 levels, whereas mRSS showed a negative correlation with IL-21(ρ� − 0.427, p � 0.050).)e increased)17-cytokine levels in
venous compared to arterial blood of patients with DU suggest local cytokine production on ulcer site.)e higher TNFa and GM-
CSF levels in arterial blood of DU patients support the attempt to mitigate the hypoxic damage, and the correlation between)17-
cytokines, mRSS, NVC, and ET1 agrees with the potent profibrotic stimulus at the onset of the disease, which decreases as the
SSc progresses.
1. Introduction
Systemic sclerosis (SSc) is an autoimmune chronic con-
nective tissue disease, affecting primarily the skin, charac-
terized by a fibrotic involvement of many organs, such as the
vascular and gastrointestinal system, lungs, and heart. Based
on cutaneous involvement, SSc can be differentiated into two
phenotypes, the diffuse SSc (dcSSc) and the limited one
(lcSSc). )e two phenotypes are also distinguishable on the
basis of visceral involvement and autoantibodies pattern.
)e earliest clinicalmanifestation of SSc is usually Raynaud’s
phenomenon (RP), a small-arteries vasospasm driven by vas-
cular tone dysregulation and microcirculatory abnormalities,
resulting in digital ulcers (DU) in up to 50% of patients [1–4].
)e vascular damage is usually rapidly progressive,
characterized by a recurrent activation and apoptosis of
endothelial cells, with consequent intimal thickening, lumen
stenosis, and vessel obliteration, leading to tissue hypoxia
and to repeated ischemia-reperfusion cycles which induce
progressive skin fibrosis.
It is well known that, as a response to vascular damage,
endothelial cells release proinflammatory cytokines such as
IL-6, IL-1β, and TNF-α and growth factors (GFs), among
which are the vascular endothelial growth factor (VEGF) [5]
and transforming growth factor β (TGF-β). )ese in-
flammatory mediators, in association with the profibrotic
stimulus of the endothelin-1 (ET-1), promote leucocyte
adhesion to the endothelium, vascular smooth muscle cell
Hindawi
BioMed Research International
Volume 2019, Article ID 7908793, 5 pages
https://doi.org/10.1155/2019/7908793
proliferation, and fibroblast activation. )is cytokine milieu
is observed particularly at sites of digital ulcers [6–8]. In fact,
other cytokines related to )-2, )-17, and )-22 have been
shown to play a role in the development of capillary damage
and fibrotic skin in patients with scleroderma [9].
Until now, no studies focused on sclerodermic digital
ulcers have analyzed the different inflammatory patterns
mirrored by cytokines measured in arterial and venous
patients’ serum.
)e aim of our study was to evaluate proinflammatory
TNF-α, )-1- (IL-2) and)-17- (IL1-β, IL-6, IL-9, IL-17, IL-
21, IL-22, and IL-23) related cytokines, TGF-β, GM-CSF,
and endothelin-1 (ET-1) in arterial and venous blood of
patients affected by systemic sclerosis with and without DU
and to analyze the correlations between cytokine levels and
clinical scores of skin fibrosis and vascular involvement.
2. Methods
2.1. Patients. All consecutive outpatients attending the
Clinic of Rheumatic Disease between May 2014 and March
2015, who received the diagnosis of SSc (according to the
ACR criteria), were enrolled in the study; the exclusion
criteria were smoking, asthma, COPD [10], history of cancer
[11] or other autoimmune disease, current corticosteroid or
immunosuppressive therapy, and current or recent (last
8weeks) systemic or respiratory infection. Arterial and
venous blood sampling, nailfold video capillaroscopy, and
modified Rodnan skin score [12, 13] were obtained in all the
patients. In patients presenting digital ulcers, both arterial
and venous blood samples were taken from the same side as
the ulcers. Our Institutional Review Board for human
studies approved the study protocol (no. 0039653), and the
study respected the Helsinki Declaration.
Venous blood samples were obtained in twenty healthy
nonsmoking subjects, who served as controls.
2.2. Cytokine Assays. Arterial and venous blood cytokines
were analyzed by multiplex immunoassay (Bio-Rad Labo-
ratories Inc., Hercules, CA, USA), with Bioplex 100 xMAP
technology (Luminex Corp, Austin, TX, USA), and Bioplex
Manager 4.1 software (Bio-Rad Laboratories, Segrate, Italy)
was used for the data analysis. Every 96-well plate included
an 8-point standard curve, and the same assay plate was used
for patient and control samples. Table 1 reports the per-
centage of samples above the detection threshold. Low cy-
tokine concentrations measured not on the linear part of the
standard curves were considered below the limit of detection
[14, 15]. Further analysis was performed on data set which
included parameters (cytokines and growth factors) mea-
sured at concentrations higher than the detection limits in
over 50% of samples.
2.3. Nailfold Videocapillaroscopy (NVC). Nailfold video-
capillaroscopic examination was performed with a epi-
luminescence video-bio-microscope for immersion
microscopy and polarized light microscopy (Videocap, DS
Medica, Milan, Italy). Each test was evaluated by two
different rheumatologists (CP and EF) using a qualitative
score based on the morphology of nailfold capillaries. )e
patterns identified within the “scleroderma pattern” in-
cluded (1) “early” NVC pattern: few enlarged/giant capil-
laries, few capillary hemorrhages, mostly well-preserved
capillary distribution, and no evident loss of capillaries; (2)
“active” NVC pattern: frequent giant capillaries, frequent
capillary hemorrhages, moderate loss of capillaries, mild
disorganization of the capillary architecture, and absent or
mild ramified capillaries; (3) “late” NVC pattern: irregular
enlargement of the capillaries, few or absent giant capillaries
and hemorrhages, severe loss of capillaries with extensive
avascular areas, disorganization of the normal capillary
array, and ramified/bushy capillaries [16].
2.4.Modified Rodnan Skin Score (mRSS). Rodnan skin score,
a semiquantitative score based on the fibrotic involvement of
the skin, according to Khanna et al. [13] was obtained from
all of the patients.
)e score ranges from 0 to 51, being analyzed in 17
different areas of the body surface, some of which considered
as double. Each area received a score ranging from 0 to 3, on
the basis of the following criteria: mRSS� 0 was “normal
skin” with fine wrinkles but no skin thickness; mRSS� 1
indicated “mild” skin thickness with possible folding be-
tween 2 fingers; mRSS� 2 corresponded to “moderate” skin
thickness with difficulty in making skin folds and no
wrinkles. mRSS� 3 indicated “severe” skin thickness with
inability to make skin folds between 2 examining fingers.
2.5. Statistical Analysis. )e statistical analysis was per-
formed using a commercially available statistical package
(STATA 10s), and only p values <0.05 were considered
statistically significant.
Based on normality distribution tests (Kolmogorov–
Smirnov, Shapiro–Wilk, and D’Agostino’s K-squared), most
cytokine concentrations were not normally distributed in
both patients and healthy controls.
A comparison between arterial and venous blood was
performed using the nonparametric test for independent or
paired samples, based on the cohort of patients (healthy
controls or patients’ group).
)e correlations between arterial or venous cytokines
and clinical (mRSS) and instrumental (NVC) parameters
were analyzed by regression analysis. Spearman’s rank
correlation coefficient was calculated according to the
nonnormal distribution of data.
3. Results
Twenty-nine patients affected by SSc (28 females and 1male)
were enrolled in the study, as well as 20 healthy controls (12
females and 8 males).
)e mean age was 64.5 years (range 28–80) in patients
and 59 years (range 47–65) in healthy subjects (n.s.). Patients
were then divided into two groups, based on the presence of
digital ulcers (20 patients) or not (9 patients). All cytokines
2 BioMed Research International
were detectable both in arterial and venous blood samples in
patients and in venous blood samples of controls.
3.1. Comparison between Venous Blood Concentration of
Cytokines in Patients and Controls. Serum levels of all the
cytokines and ET-1 were significantly higher in the patients
compared to healthy controls, except for IL-9 and IL-13
(Table 1).
3.2. Comparison between Arterial and Venous Blood Cytokine
Concentration. A significantly higher concentration of IL-
1β (p � 0.024), IL-6 (p � 0.012), IL-22 (p � 0.006), and
TGF-β (p � 0.046) was observed in venous compared to
arterial blood samples only in patients with DU, who also
showed a significantly higher concentration of GM-CSF and
TNF-alpha in arterial compared to venous blood samples
(p< 0.001) (Table 2).
No significant differences were observed between arterial
and venous cytokine concentrations in patients without
digital ulcers (Table 2).
3.3.CorrelationsbetweenCytokinesandClinicalParametersof
Capillary (NVC) and Skin (mRSS) Involvement. Venous IL-
22 (ρ� 0.460, p � 0.041), IL-23 (ρ� 0.411, p � 0.042), and
IL-17 (ρ� 0.465, p � 0.039) concentrations were positively
correlated and ET-1 (ρ� − 0.437, p � 0.044) inversely cor-
related with NVC pattern in patients with DU, who also
showed a significant correlation between NVC and arterial
TNF-α concentration (ρ� 0.460, p � 0.045). A negative
correlation between mRSS and venous IL-21 (ρ� − 0.427,
p � 0.050) was observed (Table 3).
No correlations were observed between serum cytokines
(arterial nor venous) and skin involvement in patients
without digital ulcers.
4. Discussion
)1 and )17 cytokines, as well ET-1, serum levels were
significantly higher in patients compared to controls, in-
dicating a systemic inflammatory status in patients who were
not receiving any immunosuppressive drugs.
Looking at the patients with DU, it is interesting that
they showed higher concentration of inflammatory (IL-6),
Table 2: Comparison between venous and arterial blood cytokine concentrations in patients with and without digital ulcers.
Cytokines
Patients with digital ulcers Patients without digital ulcers
Venous concentration
median (pg/ml) [CI 95%]
Arterial concentration
median (pg/ml) [CI 95%] p
Venous concentration
median (pg/ml) [CI 95%]
Arterial concentration
median (pg/ml) [CI 95%] p
TNF-α 8.51 [0.21–8.72] 28.81 [0.06–28.87] <0.001 3.78 [2.06–7.08] 1.64 [ 0.37–4.03] n.s.
IL-2 14.47 [9.95–15.03] 15.30 [11.77–15.86] n.s. 15.24 [12.81–16.70] 16.02 [7.43–17.20] n.s.
IL-5 0.33 [0.09–1.63] 0.19 [0.05–1.19] n.s. 0.30 [0.13–4.20] 0.22 [0.02–4.53] n.s.
IL-9 0.65 [0.11–3.31] 0.36 [0.13–2.47] n.s. 0.42 [0.11–1.32] 0.37 [0.17–0.62] n.s.
GM-CSF 140.88 [140.26–140.99] 141.18 [140.81–141.28] <0.001 140.99 [139.97–141.32] 141.27 [140.84–141.48] n.s.
IL-23 10.73 [7.14–11.62] 10.73 [10.58–11.68] n.s. 8.81 [4.80–10.51] 9.60 [8.49–10.74] n.s.
IL-1β 0.20 [0.17–0.64] 0.14 [0.11–0.16] 0.024 0.18 [0.03–0.67] 0.18 [0.11–0.21] n.s.
IL-6 3.71 [2.52–11.03] 1.64 [1.22–3.98] 0.012 2.09 [1.23–4.32] 1.95 [0.63–3.01] n.s.
IL-17 1.08 [0.78–1.18] 1.12 [0.94–1.33] n.s. 1.17 [0.80–1.25] 0.93 [0.48–1.34] n.s.
IL-21 23.38 [17.81–27.00] 23.38 [21.42–27.01] n.s. 23.38 [14.55–27.49] 25.36 [17.04–30.01] n.s.
IL-22 4.64 [4.13–5.30] 3.62 [3.33–4.60] 0.006 4.52 [3.42–5.23] 5.26 [4.43–5.70] n.s.
TGF-β 7.10 [6.31–13.10] 7.02 [6.44–7.06] 0.046 6.24 [3.96–11.27] 6.62 [6.17–7.13] n.s.
ET-1 14.39 [13.51–16.38] 15.88 [11.38–17.40] n.s. 15.88 [9.36–28.08] 17.37 [10.76–24.55] n.s.
Table 1: Cytokine concentrations (pg/ml) in venous blood of patients affected by SSc and in healthy controls.
Patients median [CI 95%] Healthy controls median [CI 95%] p
TNF-α 2.07 [0.21–8.72] 1.22 [0.87–1.75] 0.008
IL-2 14.57 [3.52–18.42] 6.33 [1.62–22.73] <0.001
IL-5 0.30 [0.05–10.76] 0.08 [0.00–3.38] <0.001
IL-9 0.43 [0.11–11.89] 0.90 [0.10–34.25] n.s.
IL-13 2.92 [0.42–76.85] 2.00 [0.11–9.50] n.s.
GM-CSF 140.96 [138.65–141.42] 22.28 [20.72–22.56] <0.001
IL-23 8.84 [0.60–14.79] 1.62 [1.58–1.72] <0.001
IL-1b 0.18 [0.03–1.22] 0.32 [0.20–0.97] <0.001
IL-6 3.82 [0.36–30.02] 1.23 [0.12–4.68] 0.011
IL-17 1.08 [0.41–1.65] 0.54 [0.04–0.85] 0.041
IL-21 23.38 [3.73–38.33] 3.60 [3.51–3.87] <0.001
IL-22 3.75 [0.68–6.48] 1.95 [0.59–6.37] <0.001
ET-1 15.67 [3.41–48.68] 5.42 [3.32–6.63] <0.001
TGF-β 6.62 [5.03–26.24] 4.45 [3.82–14.64] <0.001
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TGF-β, and )17 (IL-1β, IL-22) related cytokines measured
in venous compared to arterial blood, while no differences
could be appreciated in patients without DU.
)is observation suggests a local production of )1- and
)17-related cytokines, which drive a proinflammatory and
profibrotic tissue response.
Actually, )17-related cytokines, particularly IL-17A,
are thought to be involved in the pathogenesis of skin lesions
in SSc by inducing adhesion molecules production and
promoting collagen synthesis and proliferation [17]. Local
skin production of)1- and)17-related cytokines has been
found by Brembilla et al. [18], who also showed an increase
of )-22 cells in peripheral blood of patients affected by SSc,
together with an increase of IL-22 mRNA in skin biopsies,
suggesting a potential role of )-17 and )-22 in the
pathogenesis of tissue fibrosis [18–20]. In our patients, we
observed a significant correlation between )17-related
cytokines and capillary damage evaluated by NVC. In the
same patients, we showed an inverse correlation between
ET-1 levels and NVC scleroderma pattern. )is observation
may be explained by the well-known profibrotic stimulus
played by ET-1 at the onset of disease and its reduction as the
SSc progresses.
It has indeed been shown by Chora et al. that high serum
ET-1 levels were strongly related to lung and vessel fibrosis
only in patients with active SSc and not in the very early or
late phases of disease [21].
Our results also found a negative correlation between
venous IL-21 and mRSS in patients presenting DU. Zhou
and colleagues demonstrated that mRNA of IL-21 was
higher in the early phase of SSc, postulating IL-21 could be a
biomarker able to identify lesions severity in early SSc [22].
)e negative correlation we found between IL-21 and
mRSS perfectly fits with the abovementioned finding, due to
the elevated inflammation on the ulcer’s site at the onset of
disease and due to the reduction in cytokine recruitment
when skin fibrosis plays a leading role and mRSS is higher.
)e higher TNF-α and GM-CSF concentrations we
found in the arterial blood samples of patients with DU
could mitigate the hypoxic tissue damage, according to the
physiological function of these cytokines. It has been
demonstrated that the synthesis of TNF-α is increased
immediately after ischemic injury, where it plays a role in
regulating cells survival or apoptosis and in driving cellular
inflammatory responses [5, 23]. Likewise, GM-CSF is a
cytokine with pleiotropic functions, ranging from the reg-
ulation of proliferation, differentiation, and survival of he-
matopoietic cells to the mobilization and recruitment of
hematopoietic and endothelial stem cells from the bone
marrow. It also acts as a differentiation promoter of en-
dothelial cells and fibroblasts and as a stimulatory factor for
keratinocyte proliferation. To date, the efficacy of GM-CSF
intradermal administration in the treatment of chronic
venous leg ulcers is well known [24].
In conclusion, our study provides new information,
which might suggest further possible targeted therapeutic
approaches for digital ulcers of patients with scleroderma,
who are presently lacking in effective approved therapies,
except for the antagonists of ET-1.
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